概括
含糖饮料通过改变细胞代谢来促进结肠直肠癌 (CRC) 的传播. 酶SORD再生NAD+,促进CRC细胞迁移和转移,这种过程可能被他类药物抑制.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症转移的转移.
背景情况:
- 含糖饮料 (SSB) 与结直肠癌 (CRC) 发病率的增加有关.
- SSBs对CRC进展和转移的影响尚不清楚.
研究的目的:
- 研究SSB消费如何影响CRC转移.
- 为了阐明驱动SSB诱导的CRC传播的潜在代谢机制.
主要方法:
- 暴露CRC细胞系和小鼠模型的葡萄糖和果糖.
- 代谢分析以确定关键的酶和途径.
- 对SORD的基因删除和对美瓦酸路径的药理抑制.
主要成果:
- 在小鼠模型中,SSBs增强了CRC细胞迁移和肝转移.
- 酶SORD将果糖转化为,再生NAD+并增加NAD+/NADH的比率.
- SORD删除减少了CRC细胞迁移和转移;恢复NAD+/NADH救援迁移.
- 通过SORD-依赖的NAD+再生,SSBs促进糖解,TCA循环和美酸途径.
- 类他类药物抑制了SSB诱导的迁移和转移.
结论:
- 通过SORD-依赖的代谢重编程,SSBs可以增强CRC转移.
- SORD通过再生NAD+和影响关键代谢途径,将SSB消费与瘤细胞迁移和转移潜力的增加联系在一起.
相关概念视频
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Cancers Originate from Somatic Mutations in a Single Cell
14.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.5K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


